To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 4/29 cls
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) Baird Christopher Raymond Price target Neutral -3% $96.87
Jefferies Eun Yang Price target Hold
Needham Mark Monane Downgrade Hold (from buy)
Raymond raised his target to $94 from $85 after Alexion reported 1Q11 non-GAAP EPS of $0.59 last month, beating the Street's estimate of $0.51 and up 63% from $0.37 in 1Q10. Raymond feels there is additional upside to consensus estimates due to Alexion's accelerated schedule for Soliris eculizumab for atypical hemolytic

Read the full 1177 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE